Tag: next-generation in vitro diagnostics (ivd) market forecast

Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.

Next-Generation In Vitro Diagnostics (IVD) Market Size And Revenue Outlook Through 2030

The next-generation in vitro diagnostics (ivd) market has experienced rapid expansion over recent years. It is projected to expand from $117.97 billion in 2025 to $129.89 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 10.1%. The historical growth can be attributed to the rising prevalence of infectious diseases, the growing burden of chronic diseases, increased adoption of molecular diagnostics, the expansion of clinical laboratory infrastructure, and government funding for diagnostic programs.

The next-generation in vitro diagnostics (ivd) market is projected to experience substantial expansion over the upcoming years. This market is anticipated to reach a valuation of $188.69 billion by 2030, driven by a compound annual growth rate (CAGR) of 9.8%. Factors contributing to this growth during the forecast period include the escalating demand for precision medicine, the broadening scope of genomic testing applications, increased adoption of point-of-care diagnostics, the ongoing rise in healthcare digitization, and augmented investments in diagnostic research and development. Key trends anticipated throughout this period involve a shift towards personalized and companion diagnostics, the accelerated uptake of point-of-care and decentralized testing, the incorporation of multiplex and high-throughput assays, an increasing need for early disease detection and screening, and the expansion of non-invasive and liquid biopsy diagnostics.

Get A Free Sample Report With In-Depth Market Insights:

https://thebusinessresearchcompany.com/sample_request?id=33681873&type=smp&name=Next-Generation%20In%20Vitro%20Diagnostics%20%28IVD%29%20Market%20Report%202026&utm_source=Blogs&utm_medium=Paid&utm_campaign=Sep_PR

Next-Generation In Vitro Diagnostics (IVD) Market Growth Backed By Core Demand Fundamentals

Future expansion of the next-generation in vitro diagnostics (IVD) market is anticipated, fueled by the rising need for personalized medicine. Precision medicine refers to a healthcare strategy that tailors disease prevention and therapy according to an individual’s unique genetic profile, surrounding environment, and lifestyle choices. The increase in personalized medicine can be attributed to the expanding access to genomic data, empowering healthcare professionals to devise specific treatments based on an individual’s distinct genetic composition, thereby enhancing treatment efficacy. Next-generation in vitro diagnostics (IVD) plays a crucial role in supporting personalized medicine through the delivery of accurate molecular and genetic insights, facilitating customized treatment and preventive approaches for patients. As an illustration, in February 2024, data from the Personalized Medicine Coalition, a US-based hospital and health care organization, indicated that in 2023, the FDA approved 16 new personalized treatments for rare disease patients, an increase from six in 2022. Consequently, the expanding need for personalized medicine is actively fueling the growth of the next-generation in vitro diagnostics (IVD) market.

Next-Generation In Vitro Diagnostics (IVD) Market Segment Trends And Revenue Contributors

The next-generation in vitro diagnostics (ivd) market covered in this report is segmented –

1) By Product Type: Consumables, Instruments, Software

2) By Diagnostic Modality: Core Laboratory Diagnostics, Point-Of-Care Testing, Molecular Diagnostics

3) By Application: Oncology Or Cancer, Infectious Diseases, Diabetes, Cardiology , Other Applications

4) By End-User: Hospitals And Clinics, Diagnostic Laboratories, Academic And Research Institutions, Other End Users

Subsegments:

1) By Consumables: Assay Kits And Reagents, Specimen Bags and Tubes, Seals and Caps

2) By Instruments: Automated Sample Preparation Systems, High-Throughput Molecular Diagnostic Analyzers, Next-Generation Sequencing Platforms, Integrated Diagnostic Workstations And Analysis Platforms, Digital PCR Systems And Advanced Real-Time PCR Instruments

3) By Software: Laboratory Information Management Systems, Specimen Tracking Software Modules, Cloud-Based Tracking Software

Next-Generation In Vitro Diagnostics (IVD) Market Growth Trends Reshaping The Competitive Landscape

Leading companies operating in the next-generation in vitro diagnostics (IVD) market are increasingly adopting strategic partnerships. This approach in next-generation IVD involves collaborating with technology providers, research institutions, and healthcare organizations to accelerate innovation, enhance diagnostic accuracy, and expand access to advanced testing solutions for individuals, businesses, and governments. Strategic partnerships denote a process where companies leverage each other’s strengths and resources to achieve mutual benefits and success. For instance, in October 2024, Yourgene Health, a UK-based biotechnology company, partnered with Genetix, a Colombia-based human genetic diagnosis company, to launch Colombia’s first local non-invasive prenatal testing (NIPT) service. This initiative represents a significant advancement in prenatal care in the region, offering expectant parents faster, more reliable, and cost-effective access to advanced genetic screening. The service utilizes Yourgene Health’s IONA Nx NIPT Workflow, a comprehensive, CE-marked in vitro diagnostic (IVD) solution. This workflow is highly flexible and scalable, suitable for varying sample volumes, and enables Genetix to offer a quality-assured prenatal screening service within Colombia.

Next-Generation In Vitro Diagnostics (IVD) Market Industry Leaders And Competitive Landscape

Major companies operating in the next-generation in vitro diagnostics (ivd) market are F Hoffmann La Roche AG, Thermo Fisher Scientific Inc, Abbott Laboratories, Becton Dickinson And Company, Agilent Technologies Inc, Illumina Inc, Sysmex Corporation, Bio Rad Laboratories Inc, Revvity Inc, Exact Sciences Corporation, QIAGEN NV, DiaSorin SpA, Singular Genomics Systems Inc, Guardant Health Inc, Pacific Biosciences Of California Inc, Transasia Bio Medicals Ltd, J Mitra And Co Pvt Ltd, Roche Diagnostics International AG, Hologic Inc, Genetron Health Inc, Seegene Inc, BGI Genomics Co Ltd, Oxford Nanopore Technologies plc

View The Full Next-Generation In Vitro Diagnostics (IVD) Market Report:

https://thebusinessresearchcompany.com/report/next-generation-in-vitro-diagnostics-ivd-global-market-report?utm_source=Blogs&utm_medium=Paid&utm_campaign=Sep_PR

Next-Generation In Vitro Diagnostics (IVD) Market Regional Analysis And Top Geography

North America was the largest region in the next-generation in vitro diagnostics (IVD) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the next-generation in vitro diagnostics (ivd) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Reach Out To Our Team:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

How Is The Market Value Of The Next-Generation In Vitro Diagnostics (IVD) Market Projected To Expand During 2026–2030?

The next-generation in vitro diagnostics (ivd) market has experienced rapid expansion in recent years. This market is projected to grow from $117.97 billion in 2025 to $129.89 billion in 2026, at a compound annual growth rate (CAGR) of 10.1%. The growth observed in the historical period stems from the increasing prevalence of infectious diseases, the rising burden of chronic conditions, a greater uptake of molecular diagnostics, the enlargement of clinical laboratory infrastructure, and government financial support for diagnostic programs.

The next-generation in vitro diagnostics (ivd) market is projected to experience substantial expansion over the coming years. By 2030, this market is anticipated to reach $188.69 billion, demonstrating a compound annual growth rate (CAGR) of 9.8%. This projected growth is driven by factors such as the rising demand for precision medicine, the broadening applications of genomic testing, increased uptake of point-of-care diagnostics, advancing healthcare digitization, and greater investments in diagnostic research and development. Key trends expected during this forecast period encompass a move towards personalized and companion diagnostics, widespread acceptance of point-of-care and decentralized testing, the incorporation of multiplex and high-throughput assays, an escalating need for early disease detection and screening, and the expansion of non-invasive and liquid biopsy diagnostics.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=25848&type=smp

Which Strategic Drivers Are Supporting The Next-Generation In Vitro Diagnostics (IVD) Market Development?

The next-generation in vitro diagnostics (IVD) market’s future growth is expected to be propelled by the increasing demand for personalized medicine. Precision medicine is a healthcare methodology that customizes disease prevention and treatment based on an individual’s genetic profile, environment, and lifestyle. The rise of personalized medicine is due to the expanding availability of genomic data, which enables healthcare providers to develop targeted treatments specific to a person’s unique genetic makeup, resulting in more effective care. Next-generation in vitro diagnostics (IVD) aids personalized medicine by offering precise molecular and genetic insights crucial for tailoring treatment and prevention strategies for individual patients. For example, in February 2024, the Personalized Medicine Coalition, a US-based hospital and health care organization, stated that in 2023, the FDA approved 16 new personalized treatments for rare disease patients, an increase from six in 2022. Hence, the rising demand for personalized medicine is a key factor driving the expansion of the next-generation in vitro diagnostics (IVD) market.

What Are The Major Segment Categories Within The Next-Generation In Vitro Diagnostics (IVD) Market?

The next-generation in vitro diagnostics (ivd) market covered in this report is segmented –

1) By Product Type: Consumables, Instruments, Software

2) By Diagnostic Modality: Core Laboratory Diagnostics, Point-Of-Care Testing, Molecular Diagnostics

3) By Application: Oncology Or Cancer, Infectious Diseases, Diabetes, Cardiology , Other Applications

4) By End-User: Hospitals And Clinics, Diagnostic Laboratories, Academic And Research Institutions, Other End Users

Subsegments:

1) By Consumables: Assay Kits And Reagents, Specimen Bags and Tubes, Seals and Caps

2) By Instruments: Automated Sample Preparation Systems, High-Throughput Molecular Diagnostic Analyzers, Next-Generation Sequencing Platforms, Integrated Diagnostic Workstations And Analysis Platforms, Digital PCR Systems And Advanced Real-Time PCR Instruments

3) By Software: Laboratory Information Management Systems, Specimen Tracking Software Modules, Cloud-Based Tracking Software

What Trends Are Affecting The Next-Generation In Vitro Diagnostics (IVD) Market Dynamics?

Leading companies in the next-generation in vitro diagnostics (IVD) market are increasingly utilizing strategic partnerships. Within next-generation IVD, this approach entails collaborating with technology providers, research institutions, and healthcare organizations to accelerate innovation, enhance diagnostic precision, and expand access to advanced testing solutions for individuals, businesses, and governments. Essentially, strategic partnerships allow companies to leverage each other’s strengths and resources to achieve mutual benefits and success. For instance, in October 2024, Yourgene Health, a UK-based biotechnology firm, partnered with Genetix, a human genetic diagnosis company from Colombia, to launch Colombia’s inaugural local non-invasive prenatal testing (NIPT) service. This initiative represents a significant step forward in regional prenatal care, providing expectant parents with faster, more dependable, and cost-effective access to sophisticated genetic screening. The service employs Yourgene Health’s IONA Nx NIPT Workflow, a comprehensive, CE-marked in vitro diagnostic (IVD) solution. This workflow is notably flexible and scalable, suitable for varying sample volumes, thereby enabling Genetix to offer a quality-assured prenatal screening service within Colombia.

Which Companies Are Engaged In The Next-Generation In Vitro Diagnostics (IVD) Market Environment?

Major companies operating in the next-generation in vitro diagnostics (ivd) market are F Hoffmann La Roche AG, Thermo Fisher Scientific Inc, Abbott Laboratories, Becton Dickinson And Company, Agilent Technologies Inc, Illumina Inc, Sysmex Corporation, Bio Rad Laboratories Inc, Revvity Inc, Exact Sciences Corporation, QIAGEN NV, DiaSorin SpA, Singular Genomics Systems Inc, Guardant Health Inc, Pacific Biosciences Of California Inc, Transasia Bio Medicals Ltd, J Mitra And Co Pvt Ltd, Roche Diagnostics International AG, Hologic Inc, Genetron Health Inc, Seegene Inc, BGI Genomics Co Ltd, Oxford Nanopore Technologies plc

Access The Complete Next-Generation In Vitro Diagnostics (IVD) Market Report:

https://www.thebusinessresearchcompany.com/report/next-generation-in-vitro-diagnostics-ivd-global-market-report

Which Region Commands The Largest Share Of The Next-Generation In Vitro Diagnostics (IVD) Market?

North America was the largest region in the next-generation in vitro diagnostics (IVD) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the next-generation in vitro diagnostics (ivd) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access a Next-Generation In Vitro Diagnostics (IVD) Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/report/next-generation-in-vitro-diagnostics-ivd-global-market-report

Browse Through More Reports Similar to the Global Next-Generation In Vitro Diagnostics (IVD) Market 2026, By The Business Research Company

In Vitro Diagnostics Market Report 2026

https://www.thebusinessresearchcompany.com/report/in-vitro-diagnostics-global-market-report

In Vitro Diagnostic Ivd In Cardiology And Neurology Market Report 2026

https://www.thebusinessresearchcompany.com/report/in-vitro-diagnostic-ivd-in-cardiology-and-neurology-global-market-report

Bioinformatics In In Vitro Diagnostics Ivd Testing Market Report 2026

https://www.thebusinessresearchcompany.com/report/bioinformatics-in-in-vitro-diagnostics-ivd-testing-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

How Is The Market Value Of The Next-Generation In Vitro Diagnostics (IVD) Market Projected To Expand During 2026–2030?

The next-generation in vitro diagnostics (ivd) market has experienced rapid expansion in recent years. This market is projected to grow from $117.97 billion in 2025 to $129.89 billion in 2026, at a compound annual growth rate (CAGR) of 10.1%. The growth observed in the historical period stems from the increasing prevalence of infectious diseases, the rising burden of chronic conditions, a greater uptake of molecular diagnostics, the enlargement of clinical laboratory infrastructure, and government financial support for diagnostic programs.

The next-generation in vitro diagnostics (ivd) market is projected to experience substantial expansion over the coming years. By 2030, this market is anticipated to reach $188.69 billion, demonstrating a compound annual growth rate (CAGR) of 9.8%. This projected growth is driven by factors such as the rising demand for precision medicine, the broadening applications of genomic testing, increased uptake of point-of-care diagnostics, advancing healthcare digitization, and greater investments in diagnostic research and development. Key trends expected during this forecast period encompass a move towards personalized and companion diagnostics, widespread acceptance of point-of-care and decentralized testing, the incorporation of multiplex and high-throughput assays, an escalating need for early disease detection and screening, and the expansion of non-invasive and liquid biopsy diagnostics.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=25848&type=smp

Which Strategic Drivers Are Supporting The Next-Generation In Vitro Diagnostics (IVD) Market Development?

The next-generation in vitro diagnostics (IVD) market’s future growth is expected to be propelled by the increasing demand for personalized medicine. Precision medicine is a healthcare methodology that customizes disease prevention and treatment based on an individual’s genetic profile, environment, and lifestyle. The rise of personalized medicine is due to the expanding availability of genomic data, which enables healthcare providers to develop targeted treatments specific to a person’s unique genetic makeup, resulting in more effective care. Next-generation in vitro diagnostics (IVD) aids personalized medicine by offering precise molecular and genetic insights crucial for tailoring treatment and prevention strategies for individual patients. For example, in February 2024, the Personalized Medicine Coalition, a US-based hospital and health care organization, stated that in 2023, the FDA approved 16 new personalized treatments for rare disease patients, an increase from six in 2022. Hence, the rising demand for personalized medicine is a key factor driving the expansion of the next-generation in vitro diagnostics (IVD) market.

What Are The Major Segment Categories Within The Next-Generation In Vitro Diagnostics (IVD) Market?

The next-generation in vitro diagnostics (ivd) market covered in this report is segmented –

1) By Product Type: Consumables, Instruments, Software

2) By Diagnostic Modality: Core Laboratory Diagnostics, Point-Of-Care Testing, Molecular Diagnostics

3) By Application: Oncology Or Cancer, Infectious Diseases, Diabetes, Cardiology , Other Applications

4) By End-User: Hospitals And Clinics, Diagnostic Laboratories, Academic And Research Institutions, Other End Users

Subsegments:

1) By Consumables: Assay Kits And Reagents, Specimen Bags and Tubes, Seals and Caps

2) By Instruments: Automated Sample Preparation Systems, High-Throughput Molecular Diagnostic Analyzers, Next-Generation Sequencing Platforms, Integrated Diagnostic Workstations And Analysis Platforms, Digital PCR Systems And Advanced Real-Time PCR Instruments

3) By Software: Laboratory Information Management Systems, Specimen Tracking Software Modules, Cloud-Based Tracking Software

What Trends Are Affecting The Next-Generation In Vitro Diagnostics (IVD) Market Dynamics?

Leading companies in the next-generation in vitro diagnostics (IVD) market are increasingly utilizing strategic partnerships. Within next-generation IVD, this approach entails collaborating with technology providers, research institutions, and healthcare organizations to accelerate innovation, enhance diagnostic precision, and expand access to advanced testing solutions for individuals, businesses, and governments. Essentially, strategic partnerships allow companies to leverage each other’s strengths and resources to achieve mutual benefits and success. For instance, in October 2024, Yourgene Health, a UK-based biotechnology firm, partnered with Genetix, a human genetic diagnosis company from Colombia, to launch Colombia’s inaugural local non-invasive prenatal testing (NIPT) service. This initiative represents a significant step forward in regional prenatal care, providing expectant parents with faster, more dependable, and cost-effective access to sophisticated genetic screening. The service employs Yourgene Health’s IONA Nx NIPT Workflow, a comprehensive, CE-marked in vitro diagnostic (IVD) solution. This workflow is notably flexible and scalable, suitable for varying sample volumes, thereby enabling Genetix to offer a quality-assured prenatal screening service within Colombia.

Which Companies Are Engaged In The Next-Generation In Vitro Diagnostics (IVD) Market Environment?

Major companies operating in the next-generation in vitro diagnostics (ivd) market are F Hoffmann La Roche AG, Thermo Fisher Scientific Inc, Abbott Laboratories, Becton Dickinson And Company, Agilent Technologies Inc, Illumina Inc, Sysmex Corporation, Bio Rad Laboratories Inc, Revvity Inc, Exact Sciences Corporation, QIAGEN NV, DiaSorin SpA, Singular Genomics Systems Inc, Guardant Health Inc, Pacific Biosciences Of California Inc, Transasia Bio Medicals Ltd, J Mitra And Co Pvt Ltd, Roche Diagnostics International AG, Hologic Inc, Genetron Health Inc, Seegene Inc, BGI Genomics Co Ltd, Oxford Nanopore Technologies plc

Access The Complete Next-Generation In Vitro Diagnostics (IVD) Market Report:

https://www.thebusinessresearchcompany.com/report/next-generation-in-vitro-diagnostics-ivd-global-market-report

Which Region Commands The Largest Share Of The Next-Generation In Vitro Diagnostics (IVD) Market?

North America was the largest region in the next-generation in vitro diagnostics (IVD) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the next-generation in vitro diagnostics (ivd) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access a Next-Generation In Vitro Diagnostics (IVD) Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/report/next-generation-in-vitro-diagnostics-ivd-global-market-report

Browse Through More Reports Similar to the Global Next-Generation In Vitro Diagnostics (IVD) Market 2026, By The Business Research Company

In Vitro Diagnostics Market Report 2026

https://www.thebusinessresearchcompany.com/report/in-vitro-diagnostics-global-market-report

In Vitro Diagnostic Ivd In Cardiology And Neurology Market Report 2026

https://www.thebusinessresearchcompany.com/report/in-vitro-diagnostic-ivd-in-cardiology-and-neurology-global-market-report

Bioinformatics In In Vitro Diagnostics Ivd Testing Market Report 2026

https://www.thebusinessresearchcompany.com/report/bioinformatics-in-in-vitro-diagnostics-ivd-testing-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Is The Estimated Market Size Of The Next-Generation In Vitro Diagnostics (IVD) Market In 2026, And How Will Its Value Evolve By 2030?_x000D_

The market size for next-generation in vitro diagnostics (ivd) has experienced rapid expansion in recent years. It is projected to increase from $117.97 billion in 2025 to $129.89 billion in 2026, at a compound annual growth rate (CAGR) of 10.1%. During the preceding period, this growth was primarily fueled by the rising prevalence of infectious diseases, the expanding burden of chronic diseases, increased adoption of molecular diagnostics, the enlargement of clinical laboratory infrastructure, and government funding allocated for diagnostic programs._x000D_

_x000D_

The next-generation in vitro diagnostics (ivd) market size is anticipated to experience substantial growth in the coming years. It is predicted to expand to $188.69 billion in 2030, exhibiting a compound annual growth rate (CAGR) of 9.8%. This expansion over the forecast period is propelled by increasing demand for precision medicine, the broadening of genomic testing applications, the growing acceptance of point-of-care diagnostics, rising healthcare digitization, and heightened investments in diagnostic R&D. Prominent trends throughout the forecast period include a transition toward personalized and companion diagnostics, the rapid adoption of point-of-care and decentralized testing, the integration of multiplex and high-throughput assays, an escalating demand for early disease detection and screening, and the advancement of non-invasive and liquid biopsy diagnostics._x000D_

_x000D_

#Access Your Free Sample Report For In-Depth Market Analysis:#_x000D_

https://www.thebusinessresearchcompany.com/report/next-generation-in-vitro-diagnostics-ivd-global-market-report_x000D_

_x000D_

Which Major Drivers Are Influencing The Expansion Of The Next-Generation In Vitro Diagnostics (IVD) Market?_x000D_

The next-generation in vitro diagnostics (IVD) market is projected to expand, driven by the escalating need for personalized medicine. This healthcare strategy, known as precision medicine, involves tailoring disease prevention and treatment according to an individual’s unique genetic makeup, environmental factors, and lifestyle choices. The rise of personalized medicine stems from the increasing access to genomic data, empowering healthcare professionals to develop specific treatments aligned with a person’s distinct genetic profile, thereby improving treatment effectiveness. Next-generation in vitro diagnostics (IVD) plays a crucial role in personalized medicine by offering accurate molecular and genetic information, which facilitates the creation of customized treatment and prevention plans for patients. An example highlighting this trend is from February 2024, when the Personalized Medicine Coalition, a US-based hospital and health care organization, reported that the FDA approved 16 new personalized treatments for rare disease patients in 2023, a significant increase from six approvals in 2022. Consequently, the growing requirement for personalized medicine is fueling the expansion of the next-generation in vitro diagnostics (IVD) market._x000D_

_x000D_

How Is The Next-Generation In Vitro Diagnostics (IVD) Market Categorized Across Its Segment Groups?_x000D_

The next-generation in vitro diagnostics (ivd) market covered in this report is segmented – _x000D_

_x000D_

1) By Product Type: Consumables, Instruments, Software_x000D_

2) By Diagnostic Modality: Core Laboratory Diagnostics, Point-Of-Care Testing, Molecular Diagnostics_x000D_

3) By Application: Oncology Or Cancer, Infectious Diseases, Diabetes, Cardiology , Other Applications_x000D_

4) By End-User: Hospitals And Clinics, Diagnostic Laboratories, Academic And Research Institutions, Other End Users_x000D_

_x000D_

Subsegments:_x000D_

1) By Consumables: Assay Kits And Reagents, Specimen Bags and Tubes, Seals and Caps_x000D_

2) By Instruments: Automated Sample Preparation Systems, High-Throughput Molecular Diagnostic Analyzers, Next-Generation Sequencing Platforms, Integrated Diagnostic Workstations And Analysis Platforms, Digital PCR Systems And Advanced Real-Time PCR Instruments_x000D_

3) By Software: Laboratory Information Management Systems, Specimen Tracking Software Modules, Cloud-Based Tracking Software_x000D_

_x000D_

Which Trends Are Shaping The Next-Generation In Vitro Diagnostics (IVD) Market?_x000D_

Prominent companies active within the next-generation in vitro diagnostics (IVD) sector are implementing a strategic partnerships strategy. This method, applied to next-generation in vitro diagnostics, encompasses working alongside technology firms, research bodies, and healthcare providers to speed up innovation, improve diagnostic precision, and broaden the availability of advanced testing options for individuals, enterprises, and governmental entities. These strategic collaborations describe a system where organizations capitalize on one another’s strengths and assets to attain collective advantages and successful outcomes. As an illustration, in October 2024, Yourgene Health, a biotechnology company headquartered in the UK, collaborated with Genetix, a human genetic diagnosis company based in Colombia, to introduce Colombia’s inaugural local non-invasive prenatal testing (NIPT) service. This undertaking signifies a substantial progression in regional prenatal care, providing prospective parents with quicker, more dependable, and economically viable access to sophisticated genetic screening. The service employs Yourgene Health’s IONA Nx NIPT Workflow, a complete and CE-marked in vitro diagnostic (IVD) solution. Being highly adaptable and scalable, this workflow can accommodate diverse sample volumes, empowering Genetix to deliver a quality-assured prenatal screening service throughout Colombia._x000D_

_x000D_

Which Firms Are Influencing Competition In The Next-Generation In Vitro Diagnostics (IVD) Market?_x000D_

Major companies operating in the next-generation in vitro diagnostics (ivd) market are F Hoffmann La Roche AG, Thermo Fisher Scientific Inc, Abbott Laboratories, Becton Dickinson And Company, Agilent Technologies Inc, Illumina Inc, Sysmex Corporation, Bio Rad Laboratories Inc, Revvity Inc, Exact Sciences Corporation, QIAGEN NV, DiaSorin SpA, Singular Genomics Systems Inc, Guardant Health Inc, Pacific Biosciences Of California Inc, Transasia Bio Medicals Ltd, J Mitra And Co Pvt Ltd, Roche Diagnostics International AG, Hologic Inc, Genetron Health Inc, Seegene Inc, BGI Genomics Co Ltd, Oxford Nanopore Technologies plc _x000D_

_x000D_

#Get The Full Next-Generation In Vitro Diagnostics (IVD) Market Report:#_x000D_

https://www.thebusinessresearchcompany.com/report/next-generation-in-vitro-diagnostics-ivd-global-market-report_x000D_

_x000D_

Which Region Leads The Next-Generation In Vitro Diagnostics (IVD) Market In Terms Of Market Share?_x000D_

North America was the largest region in the next-generation in vitro diagnostics (IVD) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the next-generation in vitro diagnostics (ivd) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa._x000D_

_x000D_

#Request A Customized Next-Generation In Vitro Diagnostics (IVD) Market Report For Competitive Insights:#_x000D_

https://www.thebusinessresearchcompany.com/report/next-generation-in-vitro-diagnostics-ivd-global-market-report_x000D_

_x000D_

#Browse Through More Reports Similar to the Global Next-Generation In Vitro Diagnostics (IVD) Market 2026, By The Business Research Company#_x000D_

_x000D_

In Vitro Diagnostics Market Report 2026_x000D_

https://www.thebusinessresearchcompany.com/report/in-vitro-diagnostics-global-market-report_x000D_

_x000D_

In Vitro Diagnostic Ivd In Cardiology And Neurology Market Report 2026_x000D_

https://www.thebusinessresearchcompany.com/report/in-vitro-diagnostic-ivd-in-cardiology-and-neurology-global-market-report_x000D_

_x000D_

Bioinformatics In In Vitro Diagnostics Ivd Testing Market Report 2026_x000D_

https://www.thebusinessresearchcompany.com/report/bioinformatics-in-in-vitro-diagnostics-ivd-testing-global-market-report_x000D_

_x000D_

#Get in touch with us:#_x000D_

_x000D_

The Business Research Company: https://www.thebusinessresearchcompany.com/_x000D_

Americas +1 310-496-7795_x000D_

Asia +44 7882 955267 & +91 8897263534_x000D_

Europe +44 7882 955267_x000D_

Email us at info@tbrc.info_x000D_

_x000D_

#Follow us on:#_x000D_

_x000D_

LinkedIn: https://in.linkedin.com/company/the-business-research-company_x000D_

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ_x000D_

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Is The Estimated Market Size Of The Next-Generation In Vitro Diagnostics (IVD) Market In 2026, And How Will Its Value Evolve By 2030?_x000D_

The market size for next-generation in vitro diagnostics (ivd) has experienced rapid expansion in recent years. It is projected to increase from $117.97 billion in 2025 to $129.89 billion in 2026, at a compound annual growth rate (CAGR) of 10.1%. During the preceding period, this growth was primarily fueled by the rising prevalence of infectious diseases, the expanding burden of chronic diseases, increased adoption of molecular diagnostics, the enlargement of clinical laboratory infrastructure, and government funding allocated for diagnostic programs._x000D_

_x000D_

The next-generation in vitro diagnostics (ivd) market size is anticipated to experience substantial growth in the coming years. It is predicted to expand to $188.69 billion in 2030, exhibiting a compound annual growth rate (CAGR) of 9.8%. This expansion over the forecast period is propelled by increasing demand for precision medicine, the broadening of genomic testing applications, the growing acceptance of point-of-care diagnostics, rising healthcare digitization, and heightened investments in diagnostic R&D. Prominent trends throughout the forecast period include a transition toward personalized and companion diagnostics, the rapid adoption of point-of-care and decentralized testing, the integration of multiplex and high-throughput assays, an escalating demand for early disease detection and screening, and the advancement of non-invasive and liquid biopsy diagnostics._x000D_

_x000D_

#Access Your Free Sample Report For In-Depth Market Analysis:#_x000D_

https://www.thebusinessresearchcompany.com/report/next-generation-in-vitro-diagnostics-ivd-global-market-report_x000D_

_x000D_

Which Major Drivers Are Influencing The Expansion Of The Next-Generation In Vitro Diagnostics (IVD) Market?_x000D_

The next-generation in vitro diagnostics (IVD) market is projected to expand, driven by the escalating need for personalized medicine. This healthcare strategy, known as precision medicine, involves tailoring disease prevention and treatment according to an individual’s unique genetic makeup, environmental factors, and lifestyle choices. The rise of personalized medicine stems from the increasing access to genomic data, empowering healthcare professionals to develop specific treatments aligned with a person’s distinct genetic profile, thereby improving treatment effectiveness. Next-generation in vitro diagnostics (IVD) plays a crucial role in personalized medicine by offering accurate molecular and genetic information, which facilitates the creation of customized treatment and prevention plans for patients. An example highlighting this trend is from February 2024, when the Personalized Medicine Coalition, a US-based hospital and health care organization, reported that the FDA approved 16 new personalized treatments for rare disease patients in 2023, a significant increase from six approvals in 2022. Consequently, the growing requirement for personalized medicine is fueling the expansion of the next-generation in vitro diagnostics (IVD) market._x000D_

_x000D_

How Is The Next-Generation In Vitro Diagnostics (IVD) Market Categorized Across Its Segment Groups?_x000D_

The next-generation in vitro diagnostics (ivd) market covered in this report is segmented – _x000D_

_x000D_

1) By Product Type: Consumables, Instruments, Software_x000D_

2) By Diagnostic Modality: Core Laboratory Diagnostics, Point-Of-Care Testing, Molecular Diagnostics_x000D_

3) By Application: Oncology Or Cancer, Infectious Diseases, Diabetes, Cardiology , Other Applications_x000D_

4) By End-User: Hospitals And Clinics, Diagnostic Laboratories, Academic And Research Institutions, Other End Users_x000D_

_x000D_

Subsegments:_x000D_

1) By Consumables: Assay Kits And Reagents, Specimen Bags and Tubes, Seals and Caps_x000D_

2) By Instruments: Automated Sample Preparation Systems, High-Throughput Molecular Diagnostic Analyzers, Next-Generation Sequencing Platforms, Integrated Diagnostic Workstations And Analysis Platforms, Digital PCR Systems And Advanced Real-Time PCR Instruments_x000D_

3) By Software: Laboratory Information Management Systems, Specimen Tracking Software Modules, Cloud-Based Tracking Software_x000D_

_x000D_

Which Trends Are Shaping The Next-Generation In Vitro Diagnostics (IVD) Market?_x000D_

Prominent companies active within the next-generation in vitro diagnostics (IVD) sector are implementing a strategic partnerships strategy. This method, applied to next-generation in vitro diagnostics, encompasses working alongside technology firms, research bodies, and healthcare providers to speed up innovation, improve diagnostic precision, and broaden the availability of advanced testing options for individuals, enterprises, and governmental entities. These strategic collaborations describe a system where organizations capitalize on one another’s strengths and assets to attain collective advantages and successful outcomes. As an illustration, in October 2024, Yourgene Health, a biotechnology company headquartered in the UK, collaborated with Genetix, a human genetic diagnosis company based in Colombia, to introduce Colombia’s inaugural local non-invasive prenatal testing (NIPT) service. This undertaking signifies a substantial progression in regional prenatal care, providing prospective parents with quicker, more dependable, and economically viable access to sophisticated genetic screening. The service employs Yourgene Health’s IONA Nx NIPT Workflow, a complete and CE-marked in vitro diagnostic (IVD) solution. Being highly adaptable and scalable, this workflow can accommodate diverse sample volumes, empowering Genetix to deliver a quality-assured prenatal screening service throughout Colombia._x000D_

_x000D_

Which Firms Are Influencing Competition In The Next-Generation In Vitro Diagnostics (IVD) Market?_x000D_

Major companies operating in the next-generation in vitro diagnostics (ivd) market are F Hoffmann La Roche AG, Thermo Fisher Scientific Inc, Abbott Laboratories, Becton Dickinson And Company, Agilent Technologies Inc, Illumina Inc, Sysmex Corporation, Bio Rad Laboratories Inc, Revvity Inc, Exact Sciences Corporation, QIAGEN NV, DiaSorin SpA, Singular Genomics Systems Inc, Guardant Health Inc, Pacific Biosciences Of California Inc, Transasia Bio Medicals Ltd, J Mitra And Co Pvt Ltd, Roche Diagnostics International AG, Hologic Inc, Genetron Health Inc, Seegene Inc, BGI Genomics Co Ltd, Oxford Nanopore Technologies plc _x000D_

_x000D_

#Get The Full Next-Generation In Vitro Diagnostics (IVD) Market Report:#_x000D_

https://www.thebusinessresearchcompany.com/report/next-generation-in-vitro-diagnostics-ivd-global-market-report_x000D_

_x000D_

Which Region Leads The Next-Generation In Vitro Diagnostics (IVD) Market In Terms Of Market Share?_x000D_

North America was the largest region in the next-generation in vitro diagnostics (IVD) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the next-generation in vitro diagnostics (ivd) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa._x000D_

_x000D_

#Request A Customized Next-Generation In Vitro Diagnostics (IVD) Market Report For Competitive Insights:#_x000D_

https://www.thebusinessresearchcompany.com/report/next-generation-in-vitro-diagnostics-ivd-global-market-report_x000D_

_x000D_

#Browse Through More Reports Similar to the Global Next-Generation In Vitro Diagnostics (IVD) Market 2026, By The Business Research Company#_x000D_

_x000D_

In Vitro Diagnostics Market Report 2026_x000D_

https://www.thebusinessresearchcompany.com/report/in-vitro-diagnostics-global-market-report_x000D_

_x000D_

In Vitro Diagnostic Ivd In Cardiology And Neurology Market Report 2026_x000D_

https://www.thebusinessresearchcompany.com/report/in-vitro-diagnostic-ivd-in-cardiology-and-neurology-global-market-report_x000D_

_x000D_

Bioinformatics In In Vitro Diagnostics Ivd Testing Market Report 2026_x000D_

https://www.thebusinessresearchcompany.com/report/bioinformatics-in-in-vitro-diagnostics-ivd-testing-global-market-report_x000D_

_x000D_

#Get in touch with us:#_x000D_

_x000D_

The Business Research Company: https://www.thebusinessresearchcompany.com/_x000D_

Americas +1 310-496-7795_x000D_

Asia +44 7882 955267 & +91 8897263534_x000D_

Europe +44 7882 955267_x000D_

Email us at info@tbrc.info_x000D_

_x000D_

#Follow us on:#_x000D_

_x000D_

LinkedIn: https://in.linkedin.com/company/the-business-research-company_x000D_

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ_x000D_

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Size Increase Is Anticipated For The Next-Generation In Vitro Diagnostics (IVD) Market Over The 2026–2030 Period?

The next-generation in vitro diagnostics (ivd) market size has seen rapid expansion in recent years. It is projected to grow from $117.97 billion in 2025 to $129.89 billion in 2026, achieving a compound annual growth rate (CAGR) of 10.1%. Historically, this growth has been fueled by factors such as the increasing prevalence of infectious diseases, the rising burden of chronic diseases, greater adoption of molecular diagnostics, the expansion of clinical laboratory infrastructure, and government funding for diagnostic programs.

The market size for next-generation in vitro diagnostics (IVD) is anticipated to experience substantial growth in the coming years. It is projected to expand to $188.69 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 9.8%. This projected increase can be attributed to factors such as a growing demand for precision medicine, the expansion of genomic testing applications, increasing adoption of point-of-care diagnostics, rising healthcare digitization, and enhanced investments in diagnostic research and development. Significant trends expected during this forecast period include a shift towards personalized and companion diagnostics, the rapid embrace of point-of-care and decentralized testing, the integration of multiplex and high-throughput assays, an escalating demand for early disease detection and screening, and the development of non-invasive and liquid biopsy diagnostics.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=25848&type=smp

Which Major Factors Are Driving The Expansion Of The Next-Generation In Vitro Diagnostics (IVD) Market?

The burgeoning requirement for personalized medicine is anticipated to accelerate the expansion of the next-generation in vitro diagnostics (IVD) market in the future. Precision medicine, defined as a healthcare strategy, tailors disease prevention and therapy according to an individual’s genetic characteristics, surroundings, and way of life. The growth of personalized medicine stems from the increasing availability of genomic information, empowering healthcare practitioners to develop targeted therapies aligned with a person’s distinct genetic makeup, resulting in enhanced treatment outcomes. Next-generation in vitro diagnostics (IVD) plays a crucial role in personalized medicine by furnishing accurate molecular and genetic understandings, which facilitate customized treatment and preventative approaches for individual patients. For instance, in February 2024, the Personalized Medicine Coalition, a US-based hospital and health care organization, reported that in 2023, the FDA sanctioned 16 novel personalized treatments for patients with rare diseases, a significant increase from six in 2022. Consequently, the escalating demand for personalized medicine is fueling the growth of the next-generation in vitro diagnostics (IVD) market.

How Is The Next-Generation In Vitro Diagnostics (IVD) Market Segmented Across Key Categories?

The next-generation in vitro diagnostics (ivd) market covered in this report is segmented –

1) By Product Type: Consumables, Instruments, Software

2) By Diagnostic Modality: Core Laboratory Diagnostics, Point-Of-Care Testing, Molecular Diagnostics

3) By Application: Oncology Or Cancer, Infectious Diseases, Diabetes, Cardiology , Other Applications

4) By End-User: Hospitals And Clinics, Diagnostic Laboratories, Academic And Research Institutions, Other End Users

Subsegments:

1) By Consumables: Assay Kits And Reagents, Specimen Bags and Tubes, Seals and Caps

2) By Instruments: Automated Sample Preparation Systems, High-Throughput Molecular Diagnostic Analyzers, Next-Generation Sequencing Platforms, Integrated Diagnostic Workstations And Analysis Platforms, Digital PCR Systems And Advanced Real-Time PCR Instruments

3) By Software: Laboratory Information Management Systems, Specimen Tracking Software Modules, Cloud-Based Tracking Software

Which Upcoming Trends Are Expected To Influence The Next-Generation In Vitro Diagnostics (IVD) Market?

Major companies operating in the next-generation in vitro diagnostics (IVD) market are embracing a strategic partnerships approach. This method in next-generation in vitro diagnostics involves working together with technology providers, research institutions, and healthcare organizations to accelerate innovation, improve diagnostic accuracy, and expand access to advanced testing solutions for individuals, businesses, and governments. Strategic partnerships represent a process where companies leverage each other’s strengths and resources to achieve mutual benefits and success. For example, in October 2024, Yourgene Health, a UK-based biotechnology company, collaborated with Genetix, a Colombia-based human genetic diagnosis company, to launch Colombia’s first local non-invasive prenatal testing (NIPT) service. This initiative marks a substantial advancement in prenatal care within the region, offering expectant parents quicker, more reliable, and cost-effective access to sophisticated genetic screening. The service utilizes Yourgene Health’s IONA Nx NIPT Workflow, which is a comprehensive, CE-marked in vitro diagnostic (IVD) solution. This workflow demonstrates high flexibility and scalability, making it suitable for varying sample volumes, and allows Genetix to provide a quality-assured prenatal screening service within Colombia.

Who Are The Dominant Players Shaping The Next-Generation In Vitro Diagnostics (IVD) Market Landscape?

Major companies operating in the next-generation in vitro diagnostics (ivd) market are F Hoffmann La Roche AG, Thermo Fisher Scientific Inc, Abbott Laboratories, Becton Dickinson And Company, Agilent Technologies Inc, Illumina Inc, Sysmex Corporation, Bio Rad Laboratories Inc, Revvity Inc, Exact Sciences Corporation, QIAGEN NV, DiaSorin SpA, Singular Genomics Systems Inc, Guardant Health Inc, Pacific Biosciences Of California Inc, Transasia Bio Medicals Ltd, J Mitra And Co Pvt Ltd, Roche Diagnostics International AG, Hologic Inc, Genetron Health Inc, Seegene Inc, BGI Genomics Co Ltd, Oxford Nanopore Technologies plc

Read the full next-generation in vitro diagnostics (ivd) market report here:

https://www.thebusinessresearchcompany.com/report/next-generation-in-vitro-diagnostics-ivd-global-market-report

Which Region Currently Holds The Largest Share Of The Next-Generation In Vitro Diagnostics (IVD) Market?

North America was the largest region in the next-generation in vitro diagnostics (IVD) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the next-generation in vitro diagnostics (ivd) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Next-Generation In Vitro Diagnostics (IVD) Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=25848&type=smp

Browse Through More Reports Similar to the Global Next-Generation In Vitro Diagnostics (IVD) Market 2026, By The Business Research Company

In Vitro Diagnostics Market Report 2026

https://www.thebusinessresearchcompany.com/report/in-vitro-diagnostics-global-market-report

In Vitro Diagnostic Ivd In Cardiology And Neurology Market Report 2026

https://www.thebusinessresearchcompany.com/report/in-vitro-diagnostic-ivd-in-cardiology-and-neurology-global-market-report

Bioinformatics In In Vitro Diagnostics Ivd Testing Market Report 2026

https://www.thebusinessresearchcompany.com/report/bioinformatics-in-in-vitro-diagnostics-ivd-testing-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the workstation graphics processing unit (gpu) market from 2026–2035 with trusted insights from The Business Research Company

What long-term size projections exist for the Next-Generation In Vitro Diagnostics (IVD) Market covering 2026–2035?

The market size for next-generation in vitro diagnostics (ivd) has experienced rapid expansion in recent years. This market is projected to grow from $117.97 billion in 2025 to $129.89 billion in 2026, achieving a compound annual growth rate (CAGR) of 10.1%. Historically, this growth can be attributed to several factors including the rising prevalence of infectious diseases, the growing burden of chronic conditions, increased adoption of molecular diagnostics, the expansion of clinical laboratory infrastructure, and government funding allocated for diagnostic programs.

The next-generation in vitro diagnostics (ivd) market is projected to experience robust expansion over the coming years. This market is anticipated to reach $188.69 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 9.8%. Key drivers for this growth during the forecast period include a rising demand for precision medicine, the broadening scope of genomic testing applications, an increased uptake of point-of-care diagnostics, advancements in healthcare digitization, and augmented investments in diagnostic research and development. Significant trends observed in the projected period encompass a move towards personalized and companion diagnostics, widespread acceptance of point-of-care and decentralized testing methods, the incorporation of multiplex and high-throughput assays, a heightened need for early disease detection and screening, and the expansion of non-invasive and liquid biopsy diagnostics.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=25848&type=smp

Which Drivers Are Impacting The Competitive Landscape Of The Next-Generation In Vitro Diagnostics (IVD) Market?

The expanding need for personalized medicine is projected to drive the growth of the next-generation in vitro diagnostics (IVD) market moving ahead. Precision medicine refers to a healthcare strategy that tailors disease prevention and treatment according to an individual’s genetic profile, environment, and lifestyle. The surge in personalized medicine stems from the increasing availability of genomic data, enabling healthcare providers to formulate targeted treatments based on an individual’s distinct genetic makeup, resulting in enhanced care. Next-generation in vitro diagnostics (IVD) facilitates personalized medicine by offering accurate molecular and genetic insights, thereby allowing for customized treatment and prevention strategies for specific patients. As an illustration, in February 2024, the Personalized Medicine Coalition, a US-based hospital and health care organization, reported that the FDA approved 16 new personalized treatments for rare disease patients in 2023, an increase from six in 2022. Consequently, the escalating demand for personalized medicine is fueling the expansion of the next-generation in vitro diagnostics (IVD) market.

What Leading Segments Are Studied In The Next-Generation In Vitro Diagnostics (IVD) Market?

The next-generation in vitro diagnostics (ivd) market covered in this report is segmented –

1) By Product Type: Consumables, Instruments, Software

2) By Diagnostic Modality: Core Laboratory Diagnostics, Point-Of-Care Testing, Molecular Diagnostics

3) By Application: Oncology Or Cancer, Infectious Diseases, Diabetes, Cardiology , Other Applications

4) By End-User: Hospitals And Clinics, Diagnostic Laboratories, Academic And Research Institutions, Other End Users

Subsegments:

1) By Consumables: Assay Kits And Reagents, Specimen Bags and Tubes, Seals and Caps

2) By Instruments: Automated Sample Preparation Systems, High-Throughput Molecular Diagnostic Analyzers, Next-Generation Sequencing Platforms, Integrated Diagnostic Workstations And Analysis Platforms, Digital PCR Systems And Advanced Real-Time PCR Instruments

3) By Software: Laboratory Information Management Systems, Specimen Tracking Software Modules, Cloud-Based Tracking Software

Which Trends Are Influencing The Development Of The Next-Generation In Vitro Diagnostics (IVD) Market?

Leading companies in the next-generation in vitro diagnostics (IVD) market are adopting an approach centered on strategic partnerships. This method in next-generation IVD involves working with technology providers, research institutions, and healthcare organizations to accelerate innovation, enhance diagnostic accuracy, and broaden access to advanced testing solutions for individuals, businesses, and governments. Strategic partnerships represent a process where companies utilize each other’s strengths and resources to achieve mutual benefits and success. For instance, in October 2024, Yourgene Health, a UK-based biotechnology company, collaborated with Genetix, a Colombia-based human genetic diagnosis company, to launch Colombia’s first local non-invasive prenatal testing (NIPT) service. This initiative signifies a notable advancement in prenatal care for the region, offering expectant parents faster, more reliable, and cost-effective access to sophisticated genetic screening. The service incorporates Yourgene Health’s IONA Nx NIPT Workflow, which is a comprehensive, CE-marked in vitro diagnostic (IVD) solution. This workflow is highly flexible and scalable, accommodating various sample volumes, and enables Genetix to provide a quality-assured prenatal screening service within Colombia.

Which Key Market Players Are Investing In Expansion And Innovation Within The Next-Generation In Vitro Diagnostics (IVD) Market?

Major companies operating in the next-generation in vitro diagnostics (ivd) market are F Hoffmann La Roche AG, Thermo Fisher Scientific Inc, Abbott Laboratories, Becton Dickinson And Company, Agilent Technologies Inc, Illumina Inc, Sysmex Corporation, Bio Rad Laboratories Inc, Revvity Inc, Exact Sciences Corporation, QIAGEN NV, DiaSorin SpA, Singular Genomics Systems Inc, Guardant Health Inc, Pacific Biosciences Of California Inc, Transasia Bio Medicals Ltd, J Mitra And Co Pvt Ltd, Roche Diagnostics International AG, Hologic Inc, Genetron Health Inc, Seegene Inc, BGI Genomics Co Ltd, Oxford Nanopore Technologies plc

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/next-generation-in-vitro-diagnostics-ivd-global-market-report

Which Regions Are Projected To Dominate The Next-Generation In Vitro Diagnostics (IVD) Market In The Coming Years?

North America was the largest region in the next-generation in vitro diagnostics (IVD) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the next-generation in vitro diagnostics (ivd) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Next-Generation In Vitro Diagnostics (IVD) Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=25848&type=smp

Browse Through More Reports Similar to the Global Next-Generation In Vitro Diagnostics (IVD) Market 2026, By The Business Research Company

In Vitro Diagnostics Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/in-vitro-diagnostics-global-market-report

In Vitro Diagnostic Ivd In Cardiology And Neurology Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/in-vitro-diagnostic-ivd-in-cardiology-and-neurology-global-market-report

Bioinformatics In In Vitro Diagnostics Ivd Testing Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/bioinformatics-in-in-vitro-diagnostics-ivd-testing-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

How Much Larger Is The Next-Generation In Vitro Diagnostics (IVD) Market Expected To Become By 2029 Compared With Its 2025 Level?

The next-generation in vitro diagnostics (IVD) market has experienced rapid expansion in recent years. Its size is projected to increase from $106.97 billion in 2024 to $117.97 billion in 2025, achieving a compound annual growth rate (CAGR) of 10.3%. This historical development can be attributed to several factors, including an increasing geriatric population, augmented government funding, growing investments in genomic research, an uptick in clinical trials, and a rise in consumer health awareness.

The next-generation in vitro diagnostics (IVD) market size is projected to experience substantial growth in the coming years. It is expected to expand to $172.02 billion by 2029, achieving a compound annual growth rate (CAGR) of 9.9%. This projected growth during the forecast period can be attributed to the increasing development of personalized medicine, rising healthcare expenditure, an escalation in research and development activities, the growing prevalence of infectious diseases, and an increase in chronic disease cases. Major developments anticipated in the forecast period include technological innovation, the integration of artificial intelligence and machine learning into diagnostics, advanced diagnostic technologies, personalized medicine approaches, and the evolution of novel biomarkers.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=25848&type=smp

Which Drivers Are Impacting The Next-Generation In Vitro Diagnostics (IVD) Market?

The rising need for personalized medicine is projected to stimulate the expansion of the next-generation in vitro diagnostics (IVD) market in the coming years. Precision medicine represents a medical strategy that tailors disease prevention and care based on an individual’s genetic profile, environment, and lifestyle. This rise in personalized medicine stems from the increasing availability of genomic data, empowering healthcare providers to devise targeted treatments according to a person’s unique genetic makeup, which results in more effective care. Next-generation in vitro diagnostics (IVD) contributes to personalized medicine by offering precise molecular and genetic insights that facilitate tailored treatment and prevention strategies for individual patients. As an example, in February 2024, the Personalized Medicine Coalition, a US-based hospital and health care organization, reported that in 2023, the FDA granted approval to 16 new personalized treatments for rare disease patients, an increase from six in 2022. Consequently, the escalating demand for personalized medicine is fueling the growth of the next-generation in vitro diagnostics (IVD) market.

What Are The Emerging Segments Gaining Attention In The Next-Generation In Vitro Diagnostics (IVD) Market?

The next-generation in vitro diagnostics (ivd) market covered in this report is segmented –

1) By Product Type: Consumables, Instruments, Software

2) By Type: Core Laboratory Diagnostics, Point-Of-Care Testing, Molecular Diagnostics

3) By Application: Oncology Or Cancer, Infectious Diseases, Diabetes, Cardiology , Other Applications

4) By End-User: Hospitals And Clinics, Diagnostic Laboratories, Academic And Research Institutions, Other End Users

Subsegments:

1) By Software: Laboratory Information Management Systems, Specimen Tracking Software Modules, Cloud-Based Tracking Software, Barcode and Radio Frequency Identification Integration Platforms, Mobile Applications for Specimen Tracking

2) By Consumables: Barcode Labels, Radio Frequency Identification Tags, Specimen Bags and Tubes, Labeling Ribbons, Seals and Caps

3) By Hardware: Barcode Scanners, Radio Frequency Identification Readers, Label Printers, Workstations and Terminals, Storage and Transport Monitoring Devices

What Are The Latest Industry Trends Transforming The Next-Generation In Vitro Diagnostics (IVD) Market?

Major companies engaged in the next-generation in vitro diagnostics (IVD) market are adopting a strategic partnerships approach. This method in next-generation IVD involves collaborating with technology providers, research institutions, and healthcare organizations to accelerate innovation, enhance diagnostic accuracy, and expand access to advanced testing solutions for individuals, businesses, and governments. Strategic partnerships refer to a process where companies leverage each other’s strengths and resources to achieve mutual benefits and success. For instance, in October 2024, Yourgene Health, a UK-based biotechnology company, partnered with Genetix, a Colombia-based human genetic diagnosis company, to launch Colombia’s first local non-invasive prenatal testing (NIPT) service. This initiative represents a significant advancement in prenatal care in the region, offering expectant parents faster, more reliable, and cost-effective access to advanced genetic screening. The service utilizes Yourgene Health’s IONA Nx NIPT Workflow, a comprehensive, CE-marked in vitro diagnostic (IVD) solution. This workflow is highly flexible and scalable, suitable for varying sample volumes, and enables Genetix to offer a quality-assured prenatal screening service within Colombia.

Who Are The Core Companies Influencing The Next-Generation In Vitro Diagnostics (IVD) Market Landscape?

Major companies operating in the next-generation in vitro diagnostics (ivd) market are F Hoffmann-La Roche AG, Thermo Fisher Scientific Inc., Abbott Laboratories, Becton Dickinson and Company, Quest Diagnostics Incorporated, Grifols SA, Agilent Technologies Inc., Illumina Inc., Sysmex Corporation, Bio-Rad Laboratories Inc., Revvity Inc., Exact Sciences Corporation, QIAGEN NV, DiaSorin SpA, Singular Genomics Systems Inc., Guardant Health Inc., Pacific Biosciences of California Inc., Transasia Bio-Medicals Ltd., Athena Dx, J Mitra and Co Pvt Ltd

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/next-generation-in-vitro-diagnostics-ivd-global-market-report

Which Region Currently Holds The Largest Share Of The Next-Generation In Vitro Diagnostics (IVD) Market?

North America was the largest region in the next-generation in vitro diagnostics (IVD) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the next-generation in vitro diagnostics (ivd) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Next-Generation In Vitro Diagnostics (IVD) Market Report:

https://www.thebusinessresearchcompany.com/customise?id=25848&type=smp

Browse Through More Reports Similar to the Global Next-Generation In Vitro Diagnostics (IVD) Market 2025, By The Business Research Company

In Vitro Diagnostics Ivd Quality Control Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/in-vitro-diagnostics-ivd-quality-control-global-market-report

In Vitro Diagnostics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/in-vitro-diagnostics-global-market-report

In Vitro Diagnostic Ivd In Cardiology And Neurology Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/in-vitro-diagnostic-ivd-in-cardiology-and-neurology-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Current and Projected Market Size of the Next-Generation In Vitro Diagnostics (IVD) Industry?

The size of the upcoming in vitro diagnostics (IVD) market has experienced swift expansion in the past few years. The market, which was worth $106.97 billion in 2024, is projected to reach a value of $117.97 billion in 2025, growing at a compound annual growth rate (CAGR) of 10.3%. Various factors have contributed to this growth in the historic period, including an increase in the elderly population, higher government funding, more investments in genomic research, a surge in clinical trials, and enhanced health awareness among consumers.

The size of the next-generation in vitro diagnostics (IVD) market is anticipated to witness significant expansion in the upcoming years, increasing to a worth of $172.02 billion in 2029, with a compound annual growth rate (CAGR) of 9.9%. Factors contributing to this projected growth for the given duration include an uptick in the creation of personalized medicine, the rise in healthcare spending, increased focus on research and development, a growing rate of infectious diseases, and an uptick in the occurrence of chronic illnesses. Future trends projected in this period include the rise of technological innovations, the adoption of artificial intelligence and machine learning in diagnostics, advancements in diagnostic technologies, expansion in personalized medicine and the emergence of new biomarkers.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=25848&type=smp

#Which Factors Are Currently Driving The Growth Of The Next-Generation In Vitro Diagnostics (IVD) Market?

The surge in preference for personalized medicine is projected to fuel the growth of the next-generation in vitro diagnostics (IVD) market moving forward. Precision medicine, a healthcare approach that customizes illness prevention and treatment utilizing a person’s genetic profile, environment, and lifestyle, is experiencing a rise. This upswing is a result of the expanding accessibility of genomic data that enables healthcare providers to orchestrate target-specific treatments based on the patient’s distinct genetic makeup, resulting in improved care. Next-generation in vitro diagnostics (IVD) bolsters personalized medicine by yielding accurate molecular and genetic details that facilitate customized treatment and preventative measures for individual patients. For example, according to the Personalized Medicine Coalition, a US hospital, and healthcare organization, it was revealed in February 2024 that in 2023, the FDA authorized 16 new personalized therapies for rare disease patients, an increase from six in 2022. Consequently, the swelling demand for personalized medicine is spurring the growth of the next-generation in vitro diagnostics (IVD) market.

How Is The Global Next-Generation In Vitro Diagnostics (IVD) Market Structured In Terms Of Segments?

The next-generation in vitro diagnostics (ivd) market covered in this report is segmented –

1) By Product Type: Consumables, Instruments, Software

2) By Type: Core Laboratory Diagnostics, Point-Of-Care Testing, Molecular Diagnostics

3) By Application: Oncology Or Cancer, Infectious Diseases, Diabetes, Cardiology , Other Applications

4) By End-User: Hospitals And Clinics, Diagnostic Laboratories, Academic And Research Institutions, Other End Users

Subsegments:

1) By Software: Laboratory Information Management Systems, Specimen Tracking Software Modules, Cloud-Based Tracking Software, Barcode and Radio Frequency Identification Integration Platforms, Mobile Applications for Specimen Tracking

2) By Consumables: Barcode Labels, Radio Frequency Identification Tags, Specimen Bags and Tubes, Labeling Ribbons, Seals and Caps

3) By Hardware: Barcode Scanners, Radio Frequency Identification Readers, Label Printers, Workstations and Terminals, Storage and Transport Monitoring Devices

Which Trends Are Redefining The Future Landscape Of The Next-Generation In Vitro Diagnostics (IVD) Industry?

Leading corporations in the next-generation in vitro diagnostics (IVD) industry are embracing a strategic partnership approach. This involves creating alliances with technology suppliers, research institutions, and healthcare organizations to speed up innovation, boost diagnostic precision, and widen the access to sophisticated testing solutions for individuals, governments, and companies. Strategic partnerships are a strategy where companies utilize each other’s resources and strengths to reap shared advantages and achievements. For example, in October 2024, Yourgene Health, a British biotech firm, partnered with Genetix, a Colombian company specializing in human genetic diagnosis, to introduce the first local non-invasive prenatal testing (NIPT) service in Colombia. This marks a major progress in prenatal healthcare in this region, providing expecting parents with quicker, more trustworthy, and competitively priced access to advanced genetic screening. The service uses Yourgene Health’s IONA Nx NIPT Workflow, a comprehensive, CE-marked in vitro diagnostic (IVD) solution. This workflow is versatile and expandable, catering to varied sample volumes, and it empowers Genetix to provide a quality-assured prenatal screening service in Colombia.

Who Are The Main Participants Shaping The Next-Generation In Vitro Diagnostics (IVD) Market Landscape?

Major companies operating in the next-generation in vitro diagnostics (ivd) market are F Hoffmann-La Roche AG, Thermo Fisher Scientific Inc., Abbott Laboratories, Becton Dickinson and Company, Quest Diagnostics Incorporated, Grifols SA, Agilent Technologies Inc., Illumina Inc., Sysmex Corporation, Bio-Rad Laboratories Inc., Revvity Inc., Exact Sciences Corporation, QIAGEN NV, DiaSorin SpA, Singular Genomics Systems Inc., Guardant Health Inc., Pacific Biosciences of California Inc., Transasia Bio-Medicals Ltd., Athena Dx, J Mitra and Co Pvt Ltd

Get The Full Report Here:

https://www.thebusinessresearchcompany.com/report/next-generation-in-vitro-diagnostics-ivd-global-market-report

Which Region Currently Holds The Largest Share In The Next-Generation In Vitro Diagnostics (IVD) Market?

North America was the largest region in the next-generation in vitro diagnostics (IVD) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the next-generation in vitro diagnostics (ivd) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=25848&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model